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ients with a lymphocyte percentage  30% (n  153), and group
2 consists of recipients with a lymphocyte percentage 	30%
(n  165). As this is a preliminary analysis, the population has not
been limited by disease, disease status, and other potential factors
inﬂuencing outcome. Total Nucleated Cell Dose (P  .77), HLA
Matching (P  .14), and Recipient Age (P  .03), have been
evaluated to eliminate bias between the two groups. The purpose
of this analysis is to determine if a relationship exists between
lymphocyte percentage and the incidence of infection and cause of
death by infection. There was not a signiﬁcant difference in the
incidence of infection (bacterial, viral, fungal) post transplant be-
tween the two groups. Group 1 had an incidence of 131 (86%)
patients with infection, and Group 2 had an incidence of 134 (81%)
(P  .36). There was however, an extremely signiﬁcant difference
in the number of patients with a primary cause of death by infec-
tion. Group 1 experienced 73 deaths with 31 (43%) by infection,
while Group 2 experienced 75 deaths with 10 (13%) by infection
(P  .0001). With median TNC dose/kg being nearly equal be-
tween the two groups (4.0;4.5 P  .77), this preliminary analysis
indicates that there may be characteristics within the nucleated cell
populations that are critical to transplant outcome.
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ASSESSING IMMUNE FUNCTION IN ALLOGENEIC AND AUTOLOGOUS
BONE MARROW TRANSPLANT RECIPIENTS USING THE Cylex Immu-
Know ASSAY
Post, D.R.1, Martin, M.C.1, Kowalski, R.J.1 Cylex Incorporated, Co-
lumbia, MD.
The Cylex Immune Cell Function Assay (ImmuKnow) is cleared
by the FDA for the detection of cell-mediated immunity in an
immunosuppressed population. The assay measures the immune
function of CD4 T-helper cells from a small sample of whole
blood by stimulating the sample with phytohemagglutinin, selec-
tion of CD4 cells with antibody coated magnetic particles, and
detection of ATP by bioluminescence. CD4 T-helper cells that
respond to stimulating increase their production of ATP that
provide an objective measure of immune responsiveness. This test
has demonstrated clinical utility for managing immunosuppressive
therapies in solid-organ transplantation (SOT). Outcome data
from SOT recipients have identiﬁed risk zones for infection or
allograft rejection based on immune function values determined by
the ImmuKnow assay. Observational studies conducted at several
cancer centers and Universities in the United States involving over
200 patients have shown that this test provides an independent
measurement of engraftment, immune reconstitution, and immune
function in allogeneic and autologous bone marrow transplant
recipients. By assessing immune function in BMT recipients it is
possible to avoid infectious complications, manage immunosup-
pressive therapy, and scheduling of chemotherapy.
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BUSULFAN AND MELPHALAN AS PREPARATIVE THERAPY FOR STEM
CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE MY-
ELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASIA (MDS)
Andreansky, M.1, Fiederlein, R.1, Graham, M.L.1 The University of
Arizona, Tucson, AZ.
Fifty-two pediatric patients (ages 10 months to 23 years) with
primary AML (n  39), secondary AML (n  5), and MDS (n 
8) received busulfan (600 mg/m2) and melphalan (140–180 mg/m2)
with equine antithymocyte globulin (60 mg/kg) for unrelated do-
nor stem cell recipients as preparative therapy for stem cell trans-
plant. Stem cell sources consisted of allogeneic marrow (sibling
n  16, parent n  2), unrelated marrow (n  3), unrelated cord
blood (n  30), and syngeneic marrow (n  1). Regimen-related
toxicities included grade 3 or 4 mucositis (n  52) and venoocclu-
sive disease (n  3). All patients surviving 30 days demonstrated
myeloid engraftment. One hundred day survival was 77% (40/52);
100% for matched family and syngeneic donor and 64% (21/33)
for unrelated donor recipients. Causes of deaths within 100 days
were: infection / GVHD (n  6), multiorgan failure (n  2),
CNS hemorrhage (n  2), alveolar proteinosis (n  1), and trans-
fusion reaction (n 1). Of 18 patients transplanted from allogeneic
family donors, 15 survived event-free a median of 84months post
transplant; 2 of the 3 who relapsed underwent second transplants
and survived event-free 108 and 13months. Of 33 patients who
underwent unrelated donor transplants, 16 survived event-free a
median of 46 months post transplant. Four of the 33 patients
relapsed and a total of 13 died of transplant-related complications.
Of the 33 patients who received unrelated donor transplants, 9 of
15 with AML in CR1 or CR2 survived event-free a median of 60
months, 3 of 10 in relapse survived event-free 114, 107, and 8
months, and 4 of 8 with MDS survived event-free 35, 35, 23,
and 5 months. The combination of busulfan and melphalan is an
effective preparative regimen for pediatric patients with acute my-
elogenous leukemia and myelodysplasia and, in combination with
equine antithymocyte globulin, provides adequate immunosup-
pression for unrelated donor transplants.
243
IMPACT OF TIMING OF ALLOGENEIC STEM CELL TRANSPLANTATION IN
CML PATIENTS IN THE IMATINIB ERA
Schleuning, M.1, Judith, D.1, Burlakova, I.1, Baurmann, H.1,
Schwerdtfeger, R.1 Center for Hematopoietic Cell Transplantation,
Deutsche Klinik fuer Diagnostik, Wiesbaden, Germany.
Imatinib mesylate (IM), a small molecule targeting the BCR-
ABL kinase, is now considered to be the standard ﬁrst line treat-
ment of chronic myeloid leukemia (CML). Although IM induces a
high rate of cytogenetic remissions and may prolong progression-
free survival in CML patients (pts), complete molecular remissions
remain a rare event. Therefore, it remains questionable whether
IM represents a curative treatment. By contrast, the curative po-
tential of allogeneic stem cell transplantation (SCT) has been
proven. However, because of its treatment-related mortality
(TRM) nowadays SCT often is being offered to pts only after
failure of IM and thereby also delayed beyond one year after
diagnosis. The best timing for SCT for CML pts on IM remains to
be deﬁned. Therefore, we retrospectively analyzed the outcome of
all pts transplanted at our center who had received IM prior to
SCT. From the 27 consecutive CML pts included in this analysis,
11 had proven to be resistant to IM therapy. Resistance was deﬁned
by primary cytogenetic unresponsiveness or increasing percentage
of Ph metaphases or hematological progression. Fifteen pts were
transplanted in ﬁrst chronic phase and 12 in advanced disease (CP2
n  10; BC n  2). There were no signiﬁcant differences with
respect to age, donor (sibling vs unrelated), and stage of disease by
means of -square tests between the IM resistant and responding
groups. However, signiﬁcantly more pts were transplanted within
the ﬁrst year after diagnosis in the IM responding group. No
differences could be observed concerning the incidences of acute
GvHD grades II–IV, or extensive chronic GvHD between the two
groups. IM resistance was associated with a higher TRM at 100
days (36 vs 0%, P  .008) and an inferior projected overall survival
at 2 years (39 vs 70%, P .028). The poorer outcome of the IM
resistant group may be due to a longer time interval between
diagnosis and transplantation or to a transformation of the CML
clone into a more resistant leukemia requiring more aggressive
chemotherapy prior to transplantation and thus increasing the risk
of TRM. In summary, these data provide some evidence that either
IM resistance may be an adverse prognostic factor for CML pts
undergoing allogeneic SCT or that the better prognosis for pts
transplanted early during the disease also holds true in the IM era.
However, larger patient numbers and prospective trials are man-
datory to deﬁne the best timing for SCT for CML pts on IM
therapy.
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